Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

NCT05773274 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

NIH

Sponsor class

Conditions

Metastatic Digestive System Neuroendocrine Tumor G1
Metastatic Digestive System Neuroendocrine Tumor G2
Unresectable Digestive System Neuroendocrine Tumor G1
Unresectable Digestive System Neuroendocrine Tumor G2

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cabozantinib
PROCEDURE: Computed Tomography
DRUG: Everolimus
DRUG: Lutetium Lu 177 Dotatate
PROCEDURE: Magnetic Resonance Imaging
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
DRUG: Sunitinib

Sponsor

National Cancer Institute (NCI)